SPI-2012: Clinical Trials

4 completed, 1 recruiting. 2 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy Eflapegrastim, Chemotherapy - Solid Tumors, Lymphoma	Phase 2	Recruiting	Spectrum Pharmaceuticals, Inc	40	2021-05-20	2026-09-30
Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy SPI-2012 - Breast Cancer, Pharmacokinetics	Phase 1	Completed	Spectrum Pharmaceuticals, Inc	26	2017-05-11	2020-11-13
SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide SPI-2012, Pegfilgrastim, Docetaxel - Neutropenia, Breast Cancer	Phase 3	Completed	Spectrum Pharmaceuticals, Inc	237	2017-05-10	2022-03-02
SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE) SPI-2012, Pegfilgrastim, Docetaxel - Neutropenia, Breast Cancer	Phase 3	Completed	Spectrum Pharmaceuticals, Inc	406	2016-01-19	2022-03-02
Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer SPI-2012, Pegfilgrastim, Docetaxel - Neutropenia	Phase 2	Completed	Spectrum Pharmaceuticals, Inc	148	2013-03-25	2022-04-15

United States (5) · Canada (2) · Hungary (2) · Poland (2) · South Korea (2) · Australia (1) · Georgia (1) · India (1) · Israel (1)

2016 (1)